Latest Breaking News On - Acute bacterial skin - Page 2 : comparemela.com

Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023

Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesSwitzerland generalBasel stadtNorth libertyFowler jrMarc engelhardtNils schrInfectious diseases society of americaInstitute for clinical pharmacodynamicsHuman servicesAdministration for strategic preparednessUs idweek congressUs department of healthDuke clinical research instituteInternational journal of antimicrobial agentsSwiss exchange

Acurx Announces Presentation and Update of Its pol IIIC R&D Pipeline at the World Antimicrobial Resistance Scientific Congress

Ibezapolstat is currently enrolling in a Phase 2b trial for C. difficile infection in U.S. centers across the country and nearing its goal to reach a targeted.

United statesRobertj delucciaData monitoring committeeCompany phSociety or healthcare epidemiology of americaAcurx pharmaceuticals incExchange commissionTrial oversight committeeWorld antimicrobial resistance congressExchange commission on formDrug administrationAcurx pharmaceuticalsPrnewswire acurx pharmaceuticals incWorld antimicrobial resistance scientific congress onInfectious diseases society of americaInterim analysis

Global Acute Bacterial Skin and Skin Structure Infections Treatment Market Report 2023-2031: Sector to Reach $21 7 Billion by 2031 at a 9 6% CAGR

/PRNewswire/ The "Global Acute Bacterial Skin and Skin Structure Infections Treatment Market Report and Forecast 2023-2031" report has been added to.

South africaUnited arab emiratesUnited statesSaudi arabiaUnited kingdomAsia pacificLaura woodIntas pharmaceuticalsOffice hours callGlenmark pharmaceuticalsCommunity acquiredE st office hours callResearch methodologyFresenius se coSandoz international gmbZydus lifesciences

Aptorum : Reports 2022 Fiscal Year End Financial Results and Provides Business Update - Form 6-K

Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update New York & London & Paris, April 28, 2023 - Aptorum Group Limited , a. | April 28, 2023

United statesDarren luiAptorum group limitedAptorum group caymanDaptorum groupAptorum group limited nasdaqDrug administrationAptorum group formYu groupHolding groupSingapore agency for scienceAptorum group or weAptorum group limited reportsYear end financial resultsProvides businessGroup limited

Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update

Regulatory News: Aptorum Group Limited , a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today. | April 28, 2023

United statesDarren luiAptorum group or weDaptorum groupAptorum group caymanSingapore agency for scienceHolding groupAptorum group formAptorum group limited nasdaqDrug administrationYu groupRegulatory newsGroup limitedEuronext parisChief executive officerExecutive director